
Patients that discontinued due to adverse events by tested compound category for phase 1 trials Ν **Proportion** 95%-CI Effect size Antiangiogenesis 13 14.0 (8.6; 21.9)Chemotherapy (3.3; 24.2)9.5 **Immunomodulator** 19 8.3 (4.4; 15.0)Other 12 13.7 (8.7; 20.9)Receptor or signal transduction 63 12.4 (10.6; 14.5)







Effect size (95%–CI)

Test for subgroup differences: p = 0.100